Oncopeptides AB (publ) has carried out a fully guaranteed rights issue of approximately SEK 314 million.

Oncopeptides is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.

Carnegie Investment Bank, DNB Markets and Zonda Partners acted as Joint Bookrunners. Baker McKenzie acted as legal advisor to the banks with an international capital markets team consisting of Joakim Falkner, Olof Larsson and Oscar Bang in Stockholm as well as Adam Farlow in London. 

Explore Our Newsroom